SOPACHEM
ActiveSummary
SOPACHEM has been active since 1970 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €426,554 and a net result of €407,699. Equity has been growing by about 33% per year since 2018. Its solvency ranks better than 20% of 94 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Overview
Official details
Source: KBO- Status
- Active since 16-04-1970 Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21100and 1 other
- Joint committee
- 200 Aanvullend Paritair Comité voor de bedienden · annual accounts 2025
- Establishment units
- 2.004.096.511 8550 Zwevegem, since 01-04-1970
- 2.376.443.679 8560 Wevelgem, since 01-07-2025
- Financial year end
- 31 December
- Peppol
- Reachable since 12-10-2023
Board and ownership
- Helys GroupDirector · permanent representative Philippe LOIR
- Helys Group100%2025 annual accounts of Helys Group
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.6%
- Gross margin
- €943,412
- ▲ 112%
- Turnover
- ≈ €2.2m
- estimated
- Profit
- €407,699
- ▲ 91.3%
- Equity
- €426,554
- ▼ 12.7%
- Total assets
- €2.3m
- ▼ 19.5%
- Employees on 31-12-2025
- 5
- ▲ 66.7%
Score breakdownraises risk1 change of registered office in 24 monthsEquity €426,554 (18.4% of total assets)2 of the last 3 accounts latelowers riskFounded in 1970Show the evidence
Checked score
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 41% of them on solvency, 26% on liquidity, 84% on profitability and 34% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 16 days after the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Purpose
- · Gazette deed Permanent representatives: Danny Pattyn and Kathleen De Kegel
- · Gazette deed Registered office moved from Nazareth to ZwevegemResignations: Danny PATTYN, APTCO INVEST BV and 2 others · Permanent representatives: Kathleen De Kegel, Philippe LOIR and Sébastien BLAZE · Appointment: HELYS GROUP (director)
Comparable companies
These companies have the same main activity as SOPACHEM: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €618,000 and €7.3m, founded between 1971 and 2008.
| Company | Total assets | Gross margin |
|---|---|---|
| SOPACHEM Zwevegem | €2.3m | €0.9m |
| MERIDIAN BIOSCIENCE EUROPE Braine-l'Alleud | €0.6m | €0.4m |
| GREEN 2 Oostende | €2.0m | €0.1m |
| REPROBIOL Ouffet | €1.9m | €0.5m |
| DIAGAM Ath | €7.3m | €4.0m |
| PHARMACIE DE GIVRY Quévy | €1.3m | €0.5m |
| LIFRANK Wingene | €4.1m | €0.2m |
Key facts about SOPACHEM
- What is the company number of SOPACHEM?
- The company number of SOPACHEM is 0407.132.457. The VAT number is the same number with BE in front: BE 0407.132.457.
- Where is SOPACHEM based?
- The registered office is at Pluim(Z) 20, 8550 Zwevegem.Company details
- What does SOPACHEM do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
- What is the legal form of SOPACHEM?
- The legal form of SOPACHEM is Public limited company (NV).
- When was SOPACHEM founded?
- SOPACHEM was founded on 16-04-1970.
- Is SOPACHEM still active?
- Yes, SOPACHEM is an active enterprise in the KBO register.
- How many employees does SOPACHEM have?
- SOPACHEM had an average of 3.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does SOPACHEM fall under?
- In its 2025 annual accounts, SOPACHEM states joint committee 200 (Aanvullend Paritair Comité voor de bedienden).
- What is the turnover of SOPACHEM?
- The turnover in financial year 2025 is ≈ €2.2m. This figure is estimated from the gross margin of €943,412 and 2,283 comparable companies of the same size. It probably lies between €1.3m and €3.8m. It is a rough estimate.
- Is SOPACHEM profitable?
- In financial year 2025, SOPACHEM made a profit of €407,699.
- Where can I find the annual accounts of SOPACHEM?
- SOPACHEM filed 49 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of SOPACHEM due?
- SOPACHEM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.